



ANNUAL REPORT 2021

GATEWAY TO HOPE



GATEWAY
FOR CANCER RESEARCH

CONTENTS



- 3** Our Impact
- 4** From the Desk of the Chairman
- 5** Message from the President
- 6** Gateway Celebrity Fight Night
- 7** Fundraising Highlights
- 9** Ways to Give
- 10** Gateway Concierge
- 11** Research and Grants Update
- 12** Researcher Spotlight
- 13** Funded Researchers
- 14** Donor Recognition
- 18** Gateway Leadership
- 19** Financial Highlights

ABOUT GATEWAY

Gateway for Cancer Research accelerates practice-changing discoveries in cancer care by harnessing the unrelenting passion of the cancer research community and empowering informed patients to triumph over their disease. Gateway awards grants to clinician-scientists that advance early phase clinical trials at the vanguard of discovery science, bringing breakthroughs to the bedside for patients around the world.

All of this is guided by a **clear vision**: To shape a world in which a cancer diagnosis is no longer feared.

OUR CHALLENGE

Cancer is a complex, global, public health threat that calls for a worldwide response. Ending cancer as we know it requires a shared vision and collective drive of researchers, physicians and philanthropists to bring to life the novel, patient centered ideas that lead to transformational breakthrough therapies and cures.

Together, we are a gateway to hope for the 18 million people in the world who will receive a cancer diagnosis this year.

OUR IMPACT

At Gateway, it is always and only about the patient. Thanks to generous underwriting by the Stephenson family, an astonishing 99 cents of every dollar donated directly funds transformational cancer clinical trials around the world.

190+ 

CANCER CLINICAL TRIALS FUNDED WORLDWIDE

60+ 

ACTIVE STUDIES FOR CANCERS OF ALL TYPES

99 CENTS

OF EVERY DOLLAR DIRECTLY FUNDS CANCER RESEARCH

9,900+ 

PATIENTS ENROLLED IN GATEWAY-FUNDED STUDIES

\$95+ 

MILLION RAISED FOR INNOVATIVE CLINICAL TRIALS



Cancer: A Global Public Health Challenge

18 MILLION PEOPLE in the world are diagnosed with cancer annually.

Cancer accounts for **9.5 MILLION DEATHS** worldwide each year.

In the U.S., nearly **1.9 MILLION NEW CANCER CASES** will be diagnosed in 2021.

This year it is estimated that more than **600,000 AMERICANS WILL DIE FROM CANCER.**

Sources: National Cancer Institute Surveillance, Epidemiology, and End Result Program (SEER) Study; World Health Organization data reported for 2018.



FROM THE DESK OF THE CHAIRMAN

In a year like no other, when the global pandemic brought hardship to all and unimaginable challenges to those facing cancer, my message is simple: THANK YOU. On behalf of patients, families and cancer researchers around the world, thank you for supporting Gateway for Cancer Research in our mission to deliver breakthrough cancer clinical trials that make a meaningful difference in patients' lives.

For cancer patients and the dedicated physician-researchers who work tirelessly to cure them, three words come to mind: *courage*, to face cancer; *strength*, to overcome it; and *resilience*, to meet the challenges head-on and drive forward with purpose. Never have these words held more meaning, nor has our mission been more urgent, than at this extraordinary moment in world history.

This is also a moment to celebrate our many successes. Since its founding 30 years ago, Gateway has invested more than \$95 million in transformative, early phase clinical trials that are changing the face of cancer care NOW. As you read this, thousands of men, women and children participating in Gateway-funded clinical trials are feeling better, living longer, and conquering cancer TODAY.

This is all thanks to you, our generous supporters who have joined us to bring breakthroughs to the bedside for courageous patients around the world who are desperately seeking ways to overcome their cancer.

While we celebrate this milestone in advancing cancer research and patient care, we resoundingly reaffirm that we will not stop demanding more until we end cancer once and for all. Together with you, Gateway will fulfill our shared vision to create a world in which a cancer diagnosis is no longer feared.

As always, with deepest gratitude and appreciation,

Richard J Stephenson
Chairman of the Board
Gateway for Cancer Research



A MESSAGE FROM THE PRESIDENT

Gateway achieved a remarkable milestone in 2021 – Our 30th year of advancing transformational early phase cancer clinical trials that help patients feel better and live longer as we shape a world in which a cancer diagnosis is no longer feared.

We acknowledge the grief and loss the entire world continues to experience as the COVID-19 pandemic evolves. And we are awed by the resilience of our global cancer community in meeting the pandemic's unprecedented challenges.

Cancer didn't stop for COVID. Neither did Gateway. At a time when many organizations pulled back, Gateway drove forward with determination. With cancer patients as our singular focus, we launched *Extraordinary Measures*, an innovative program that brings cancer clinical trials directly to their doorsteps, ensuring patient access to potentially life-saving investigational therapies. Through the extraordinary generosity of our donors, Gateway raised close to \$3 million for patient-centered, site-less clinical trials, and through the ingenuity of physician-researchers, these trials are underway. Gateway is energized to fuel the engine of cancer discovery through the pandemic and beyond.

Extraordinary Measures helped us reach another incredible milestone this year: Gateway awarded just under \$10 million in grants for innovative clinical trials, each of which holds practice-changing potential and raises the bar in cancer care. That's the highest one-year amount in Gateway's 30-year history!

Our success is dependent upon the generosity of supporters who are inspired by the depth and breadth of our mission and share our vision for the future. This year has been one of notable discoveries and accomplishments, none of which would have been possible without you, our generous donors. On behalf of the entire Gateway team and the patients we are privileged to serve, thank you for your commitment and partnership.

Resilience is defined as the ability to recover from or easily adjust to misfortune or change. Together, looking forward, we will persevere in our mission and achieve our ultimate milestone – an end to cancer as we know it.

Warm regards,

A handwritten signature in black ink that reads "Michael Burton". The signature is fluid and cursive, written in a professional style.

Michael Burton
President and CEO
Gateway for Cancer Research

A KNOCK-OUT PUNCH FOR CANCER



GATEWAY CELEBRITY FIGHT NIGHT A GATEWAY FOR CANCER RESEARCH GALA

This spring, **Gateway for Cancer Research and Celebrity Fight Night (CFN)** joined forces to expand our collective impact and philanthropic power to defeat cancer.

CFN is an internationally-recognized philanthropic organization whose charity events are synonymous with celebrity support for advances in health and well-being. Since its founding by Jimmy Walker in 1994, CFN has granted more than \$90 million to the Barrow Neurological Institute in Phoenix and several other health and wellness nonprofits. Gateway's Chairman, Richard J Stephenson and Vice Chair, Dr. Stacie J. Stephenson have long been proud sponsors of Celebrity Fight Night and its charitable mission.

The Stephensons now take the helm of CFN to usher in the next era for this incredible event. Sean Currie, who joined CFN in 1997 and has been instrumental in its fundraising success, continues in his role as Executive Director, partnering with Gateway in its mission to fund transformative, patient-centered, clinical cancer research.

In our almost 60-year collective history, our two organizations have raised more than \$180 million for medical research that makes a meaningful difference in the lives of so many. The new partnership will only accelerate the realization of Gateway's vision to end cancer as we know it.

SAVE THE DATE

March 12, 2022 | Phoenix, Arizona





FUNDRAISING HIGHLIGHTS

VINO CON STELLE - AN EVENING UNDER THE STARS

The stars aligned in spectacular fashion on April 23, 2021 at the fourth annual *Vino con Stelle*, an Arizona fundraising event which raised a record-breaking **\$772,000** for transformational early phase cancer research.

Vino con Stelle is a world-class culinary, wine and star-studded philanthropic experience that celebrates the breakthrough advances in cancer research and patient care that are made possible when leading cancer researchers, physicians and philanthropists come together with passion and purpose.

Global philanthropists Dr. Stacie J. Stephenson, Vice Chair of Gateway, and Richard J Stephenson, Gateway Founder and Chairman, served as hosts and co-chairs for the event, held at the Royal Palms Resort and Spa in Phoenix. Multiple Emmy Award-winning journalist Tara Hitchcock emceed an amazing event, featuring live performances by recording artists

Pia Toscano, Loren Allred, Justin Guarini and William Joseph. Pulitzer Prize-winning author, oncologist and Gateway-funded investigator Siddhartha Mukherjee, MD, DPhil, delivered a keynote address.

Guests enjoyed wines curated by renowned restaurateur Mark Tarbell. Arizona Cardinals wide receiver Larry Fitzgerald was honored with Gateway's prestigious Leadership in Cancer Advocacy Award, for his outstanding advocacy on behalf of cancer patients and his efforts to advance treatments and cures for cancer.

Gateway extends our deepest gratitude to the *Vino con Stelle* host committee members and all who came together for an evening under the stars. Thank you for joining us in our life-saving mission to fund the transformative cancer research that will forever change the face of cancer care.



EXTRAORDINARY MEASURES YIELDS EXTRAORDINARY RESULTS

For the nearly 5,000 Americans every day who receive a cancer diagnosis, the global COVID-19 pandemic delivered a double dose of complexity and heartache. Many vulnerable cancer patients opted to delay treatment, and clinical trials were suspended as cancer centers reallocated resources to pandemic response. Countless cancer patients around the world had limited access to clinical trials of promising investigational therapies.

To address this unprecedented threat to cancer care and clinical research, Gateway launched *Extraordinary Measures*, an innovative grant program to fund “site-less” early phase clinical oncology studies that leverage technologies like telemedicine, wearables and smartphone apps, and remote monitoring to improve patient access to cancer clinical trials.

Extraordinary Measures has raised nearly \$3 million for innovative, patient-centered, site-less cancer clinical trials, and has two funded studies currently underway.

Sameek Roychowdhury, MD, PhD, of The James Comprehensive Cancer Center at The Ohio State University, is leading a clinical trial that

delivers molecular profiling to the doorsteps of patients with certain rare solid tumor cancers, utilizing telehealth consultation with local oncology practices.

At Princess Margaret Cancer Centre in Toronto, Canada, Gary Rodin, MD, is studying the efficacy of iCALM, an online mental health program to help patients and their caregivers better manage the psychosocial implications of living with advanced cancer, improving quality of life and expanding access for those who cannot attend the in-person CALM program.

Cancer didn't stop for the pandemic. Thanks to *Extraordinary Measures*, neither did Gateway. We have additional site-less clinical trial applications currently under review for funding and have extended our search for the most promising patient-centered research until the end of 2021.

We are deeply grateful for the generosity of many donors who seized the opportunity to make a meaningful difference in the lives of those facing cancer at a time of unprecedented need.



30TH ANNIVERSARY CURES GALA - STARDUST DREAMS

We're getting ready to have a ball! The *Cures Gala*, co-hosted by Dr. Stacie J. and Richard J Stephenson and held on **November 13, 2021**, will be an unforgettable celebration of an incredible milestone: Gateway's 30th year of advancing transformational research that gives those facing cancer and their loved ones more options, more time, and better quality of life.

Since 1991, Gateway has been harnessing the shared passion and collective drive of world-class cancer researchers, physicians and philanthropists to advance innovative, early phase clinical trials, all of which have the potential to make a meaningful difference in patients' lives. The *30th Anniversary Cures Gala - Stardust Dreams* will be a stellar celebration of all that we have achieved, together, in support of our vision: To shape a world in which a cancer diagnosis is no longer feared.

Gateway deeply appreciates your support in making this milestone event the most successful yet. All proceeds will directly support clinical trials funded by Gateway for Cancer Research. For more information, contact Natalie Stewart, Chief Advancement Officer, at natalie.stewart@gatewaycr.org.



WAYS TO GIVE

There are many ways to support Gateway's vital cause.

Event Sponsorship

Sponsor a Signature Event and make a meaningful impact in the fight against cancer

Make a Donation

Fund any amount to help Gateway advance its vision of shaping a world in which a cancer diagnosis is no longer feared



DIY Fundraiser

Gateway provides all the resources you need for a successful event

In-Kind Gifts

Gifts of merchandise or experiences create excitement at events and provide impactful marketing exposure

Tribute Gifts

Show how much your friend or loved one means to you by making a donation in their honor



Life Insurance

Create an inspirational legacy by naming Gateway as a beneficiary of a life insurance policy that you and your family may no longer need

Stocks

Gifts of stock will help continue Gateway's funding of lifesaving research

Wills and Bequests

Include Gateway to create a lasting testament to your giving

Gateway Concierge

Tailor a novel research program inspired by your passion to drive innovative discoveries in cancer care

Charitable Trusts

Make a difference by directly supporting cancer trials

Corporate Social Responsibility Partner

Share your passion for funding breakthrough cures through support from your organization



Volunteering

Give the gift of your time by joining a committee or attending an event



CONCIERGE
BY GATEWAY FOR
CANCER RESEARCH

PERSONALIZED PHILANTHROPY IN PURSUIT OF CANCER CURES

Gateway's exclusive cancer philanthropy experience, *Gateway Concierge*, ignites visionary collaboration between global philanthropists and world-class clinician-scientists whose breakthroughs are changing the face of cancer care. Launched in 2019, the program aligns high-impact donors who want to make a meaningful difference in the fight against cancer – those who understand the importance of funding early phase research and value the relational nature of personalized philanthropy – with those research leaders who can deliver results.

Through *Concierge*, Gateway and the donor co-design a novel research program that speaks directly to a donor's individual experience, passion, and philanthropic intentions to advance cancer research. Gateway then engages the global cancer research community to identify, through rigorous peer review, the most promising research teams who can deliver on the donor's vision.

Gateway is pleased to announce its fourth *Concierge* gift, the generous commitment of \$250,000 from Joe Caltabiano, CEO and Director, Choice Consolidated Corp. and a member of Gateway's board of directors. This follows a gift of \$250,000 from Andi and Jim Gordon, founder and managing partner of The Edgewater Funds; a \$750,000 gift from Muneer Satter, founder and chairman of Satter Investment Management; and the inaugural *Concierge* gift of \$250,000 from healthcare entrepreneur Raj Mantena. We gratefully acknowledge these enterprising philanthropists whose generosity is changing the face of cancer care.



DONOR SPOTLIGHT: RAJ MANTENA, RPh Chairman and Founder, Integra Connect

As a healthcare entrepreneur in the business of providing specialty practice management services to cancer centers for more than 25 years, inaugural *Concierge* donor Raj Mantena has firsthand

knowledge of the cancer patient's experience, from diagnosis through treatment and beyond.

"I see the challenging journey cancer patients go through," Mantena says. "The whole process – which Integra Connect is at the forefront of managing – can be overwhelming. It's hard not to be affected by the experience of patients and their families."

With an educational background in clinical pharmacy, Mantena also knows a great deal about the drug development process, and the importance of patient access to early phase clinical trials.

Simply put, "Early phase research saves lives," he says.

Mantena brings that experience and deep desire to help those facing cancer to his partnership with Gateway in co-creating a research program in precision medicine.

In the broadest sense, precision medicine involves sequencing a patient's tumor to identify the gene mutations that drive the cancer, then tailoring therapies to target those alterations. To clinician-researchers and those like Mantena, it also means matching a patient with the most promising clinical trial based on the genetics of their individual tumor.

Mantena's generous gift will support an early phase clinical trial using telemedicine to bring a novel

blood-based genomic test – a precision diagnostic – to patients with a rare type of liver cancer.

Sameek Roychowdhury, MD, PhD, of The James Comprehensive Cancer Center at The Ohio State University is leading a clinical trial of this "liquid biopsy" that detects and evaluates DNA fragments shed into the blood by the patient's tumor.

The James oncologists who specialize in treating cholangiocarcinoma use the genomic analysis to match these patients to clinical trials of investigational therapies for their

disease. While patients can benefit from the cutting edge genomic testing and clinical expertise found at academic cancer centers like The James, most cannot travel long distances or pay expensive out-of-pocket costs for this expert level of care. Through telemedicine, Dr. Roychowdhury's clinical trial, made possible by Mantena's *Concierge* gift, offers patients expert care and access to the latest personalized therapies for their cancer, and sets the stage for future clinical trials of precision diagnostics for cancer.

"Early phase research gives us the best opportunity for helping patients," Mantena says. "Even if it were to save only a few lives, or give us a just a few new treatment options, it's so important. Everyone should champion early phase research."

**"Early phase
research
saves lives."**

- Raj Mantena, RPh

THE POWER OF PARTNERSHIPS – A RESEARCH AND GRANTS UPDATE

Gateway invests in innovative early phase research that has the potential to shift the paradigm for standard of care and make a meaningful difference in the lives of cancer patients. Through partnerships with like-minded organizations, Gateway is moving the needle against cancer.

CONQUER CANCER® THE ASCO FOUNDATION

Gateway's scientific partnership with the philanthropic foundation of the **American Society of Clinical Oncology (ASCO), Conquer Cancer®** advances cancer research through two programs.

- A \$50,000 **Young Investigator Award (YIA)** supports the next generation of clinician-scientists at the beginning of their careers. The 2021 recipient Ivan de Kouchkovsky, MD, of the University of California, San Francisco, is working to develop new targeted treatment approaches for men with advanced, metastatic prostate cancer.
- The prestigious **Discovery Grant Program** funds a compelling area of inquiry with a \$1.5 million grant awarded every two years. Gateway announced the 2022 Discovery Grant which, when awarded, will provide funding to catalyze innovative clinical research with a strong potential impact on mitigating cancer health disparities within underrepresented patient populations and improving equitable access to cancer clinical trials.

NIH NATIONAL CANCER INSTITUTE

Gateway announced a new partnership with the **National Cancer Institute (NCI)** to support Specialized Programs of Research Excellence (**SPORE**)/**P20** grant recipients with additional funding to complete critical translational research. Highly competitive and prestigious **SPORE** grants are the **NCI's** funding mechanism designed to enable rapid and efficient translation of basic scientific findings into the clinic. The nation's top multi-disciplinary cancer research teams at leading cancer centers advance breakthrough discoveries for patients through **SPORE** funding. Gateway has committed \$2.5 million in funding for three to four clinical trials in the inaugural year of this program.

SIO SOCIETY FOR Integrative Oncology

Gateway is focused on funding evidence-based integrative oncology research that aims to increase quality of life, especially during and post-treatment. To bring the most promising patient-centered, integrative oncology research proposals forward, Gateway is partnering with **SIO** to support integrative clinical trials conducted by principal investigators and institutions among its membership. **SIO's** mission is to advance evidence-based, comprehensive, integrative healthcare to improve the lives of people affected by cancer.

RISING TIDE® Foundation

Gateway provides scientific review support and post-award grant management services for this Switzerland-based foundation.

EORTC European Organisation for Research and Treatment of Cancer

The future of cancer therapy

EORTC is a non-governmental, non-profit organization which unites clinical cancer research experts throughout Europe to advance cancer treatment and improve patients' quality of life. In 2021, Gateway announced an award over \$500,000 to **EORTC** for an international, 40-site clinical trial evaluating a novel combination molecularly-targeted therapy and radio-chemotherapy to reduce treatment toxicities and improve outcomes for adolescents and adults with a rare brain cancer, medulloblastoma.



RESEARCHER SPOTLIGHT: RACHEL BLITZBLAU, MD, PhD

Pre-operative Breast Radiotherapy: A Tool to Provide Individualized and Biologically-Based Radiation Therapy

While there are several different types of breast cancer, the initial treatment approach is more or less the same for most women – surgery

to remove the tumor followed by radiation to destroy any cancer cells that may have been left behind. A Gateway-funded study, led by Rachel Blitzblau, MD, PhD, is moving away from this “one-size-fits-all” radiation therapy toward a more targeted approach based on the genetic characteristics of an individual woman’s tumor.

Dr. Blitzblau and her colleagues at Duke University Cancer Center recently completed a Phase II trial that successfully treated women with radiation before surgery. The main benefit of the pre-surgical approach, she found, is that an intact breast is a more reliable target for radiation therapy, meaning less of the surrounding normal tissue is exposed to high-dose radiation.

“Our goal with radiotherapy is to precisely target the tumor to spare as much healthy tissue as possible from receiving the radiation dose,” Blitzblau says. “We found this much easier to do before surgical removal of the tumor, when the breast was still fully intact. This is reflected in our good patient outcomes.”

Dr. Blitzblau found the pre-operative radiation to be well-tolerated with excellent cosmetic outcomes for patients. The vast majority of patients reported they were very satisfied or extremely satisfied with the pre-operative radiation therapy, and all of them said they would choose this treatment again, if needed.

“For me personally, this was a ‘walk in the park’ part of the breast cancer story,” says a patient of Dr. Blitzblau. “I had no down time during the pre-operative radiation, no side effects. I hope this clinical trial will be available for others that fit the profile because it takes the unexpected out of having breast cancer.”

The pre-operative approach also gives researchers a unique opportunity to identify

and test breast cancer radiation response biomarkers, and personalize therapy accordingly. The team collected pre- and post-radiation MRI images, and tumor tissue and blood samples for gene sequencing to learn more about how individual subtypes of breast cancer respond to radiation. With this information, doctors can tailor the dosage so women with more sensitive tumors can receive less toxic treatment and those with more aggressive cancer can receive more effective radiation.

“For me personally, this was a ‘walk in the park’ part of the breast cancer story. I had no down time during the pre-operative radiation, no side effects. I hope this clinical trial will be available for others that fit the profile because it takes the unexpected out of having breast cancer.”

- Patient of Dr. Blitzblau

In the longer term, Dr. Blitzblau will continue to track patient outcomes in search of opportunities to fine-tune the radiation therapy. She also sees the potential for expanded approaches, such as combining pre-operative radiation therapy with immunotherapy or chemotherapy in higher risk patients, for example.

The ultimate goal of the research is to improve upon current radiation methods that treat all breast cancers alike with an individualized approach based on tumor characteristics. That could be an initial treatment game-changer for millions of women diagnosed with breast cancer.

“I am three years cancer-free, which is the ultimate goal in this process. I would do it all over again,” the patient said. “I hope this radiation treatment will be a part of cancer care going forward.”

FUNDED RESEARCHERS

Be the Match Foundation®

Dr. Steven Devine

Boston Children's Hospital

Dr. Alexandra Carey

Children's Hospital Los Angeles

Dr. Hisham Abdel-Azim

Dr. Fariba Navid

Dr. Nathan Robison

Dr. Alan Wayne

Cincinnati Children's Hospital Medical Center

Dr. Stella Davies

Dr. Parinda Mehta

City of Hope

Dr. Christine Brown

Dr. Sumanta Pal

Cleveland Clinic

Dr. Miriam Cremer

Dr. David Levy

Dana-Farber Cancer Institute

Dr. Toni Choueiri

Dr. Suzanne Forrest

Dr. Rachel Freedman

Dr. Rizwan Romee

Dr. Jonathan Schoenfeld

Dr. Sara Tolaney

Duke University Cancer Center

Dr. Rachel Blitzblau

Emory University School of Medicine

Dr. Craig Hofmeister

Geneva University Hospital

Dr. Nicholas Mach

George Mason University

Dr. Emanuel Petricoin

Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute

Dr. John Levine

Johns Hopkins University

Dr. Nilofer Azad

Dr. Lei Zheng

Karmanos Cancer Institute

Dr. Abhinav Deol

Massachusetts General Hospital Cancer Center

Dr. Marcela Maus

Dr. David Ting

MD Anderson Cancer Center

Dr. Lorenzo Cohen

Dr. Ecaterina Ileana Dumbrava

Dr. Amol Ghia

Dr. Nancy Gordon

Dr. Aung Naing

Dr. Ajay Sheshadri

Dr. Nizar Tannir

Dr. Yinghong Wang

Dr. Shiao-Pei Weathers

Dr. Shannon Westin

Dr. Mark Zafereo

Memorial Sloan Kettering Cancer Center

Dr. Connie Batlevi

Dr. Lee Jones

Dr. Dana Rathkopf

Dr. Linda Vahdat

Ottawa Hospital Research Institute, Canada

Dr. Rebecca Auer

Princess Margaret Cancer Centre

Dr. Gary Rodin

Royal College of Surgeons

Dr. Bryan Hennessy

Rutgers, The State University of New Jersey

Dr. Isaac Kim

Seattle Children's Hospital

Dr. Sarah Leary

Sheba Medical Center

Dr. Yaacov Lawrence

St. Jude Children's Research Hospital

Dr. Michael Bishop

Dr. Tanja Gruber

Dr. Jeffrey Rubnitz

The James Comprehensive Cancer Center at The Ohio State University

Dr. Maryam Lustberg

Dr. Sameek Roychowdhury

The Wistar Institute

Dr. Dario Altieri

University of Alabama at Birmingham

Dr. James Markert

University Hospital Basel

Dr. Christoph Mamot

Dr. Sacha Rothschild

University Hospital, Inselspital

Dr. Adrian Ochsenbein

University of California, San Francisco

Dr. Sabine Mueller

University of Iowa

Dr. Bryan Allen

University of Michigan

Dr. Yoshie Umemura

University of Rochester

Dr. David Linehan

University of Texas Southwestern Medical Center

Dr. Muhammad Beg

Dr. David Gerber

Dr. Dominic Moon

University of Utah

Dr. Anupam Verma

Universitaetsklinikum Regensburg (EORTC)

Dr. Peter Hau

Yale University

Dr. Ranjit Bindra

THANK YOU TO OUR DONORS

On behalf of the patients, families, and clinician-scientists around the world for whom your donations are making a difference, thank you for supporting Gateway for Cancer Research and the quest to create a world in which a cancer diagnosis is no longer feared.

Every donor and every dollar make a meaningful difference in the fight against cancer. Your generosity is making possible some of the most innovative, transformational clinical trials that will end cancer as we know it.

CHAIRMAN'S CIRCLE

\$100,000 and Above

Dr. Stacie J. and
Mr. Richard J Stephenson
Cancer Treatment Centers of America®
Mr. and Mrs. Joseph Caltabiano
Clune Construction Company
The Edgewater Funds,
Andi and Jim Gordon
International Private Bank
Mr. and Mrs. Raj Mantena
The Marian G. Harrison Trust
Rising Tide Foundation
Satter Foundation
Stellar Insurance
Templer Family Foundation

VISIONARIES CIRCLE

\$50,000 - \$99,000

CTCA Phoenix
Ms. Mary Gerdtz and
Mr. Douglas McKinney
Mr. and Mrs. Jim Hebets,
The Comp Consulting Companies
Mr. and Mrs. Darren P. Keller
Dr. and Mrs. Christopher Stephenson

CIRCLE OF IMPACT

\$25,000 - \$49,000

AmerisourceBergen
Mr. and Mrs. Michael Entzminger
Mr. and Mrs. Wally Henkel
Mr. Thomas Hoganson
Mrs. Annie Stephenson Hostetler and
Mr. William Hostetler
Mr. Bill Pope
Mr. and Mrs. Rob Walton

CIRCLE OF INNOVATION

\$10,000 - \$24,999

Dr. Ed Chu
Mr. and Mrs. Timothy Flanigan
Mr. and Mrs. Bill Grogan
Mr. and Mrs. James Grogan
Mr. and Mrs. Charles Harris
The Kelly Foundation
Mr. and Mrs. Bruce S. Lubin
Mr. and Mrs. George Lund
Mr. and Mrs. Dennis Lynde
Mrs. Lisa McCullagh
The Honorable Stephen Manrose
and Mrs. Janet Horn
Phoenix Children's Hospital
Mr. and Mrs. Tom Reahard
Mr. and Mrs. Tim Schaub
The Shirley C. Caris Family Foundation
Mr. and Mrs. James V. Stibgen
Mr. and Mrs. Shane Thompson
University of Phoenix
Mr. and Mrs. Richard A. York

CIRCLE OF HOPE

\$1,000 - \$9,999

Ms. Robyn Andrews
Arizona Diamondbacks
Dr. and Mrs. Pat Basu
Mr. and Mrs. Thomas Blake
Mr. Matthew Boland and
Mr. Christopher Greulich
Ms. Tanya Bonaparte
Dr. Tammy Born
Dr. and Mrs. John Brown
Mrs. Stella Centeno
Dr. Robert Childress
Ms. Yekaterina Chudnovsky
Mr. and Mrs. Joey Ciolli
Mr. Michael Cohen
Mr. and Mrs. Gary Contreras

Mr. and Mrs. Joe Courtney
Ms. Zalenda Cyrille
Mr. and Mrs. Hanley Dawson III
Mr. and Mrs. Larry Day
Mr. and Mrs. Fred DeGrandis
Ms. Horalia Dolmuz
Mr. and Mrs. Tony Festa
Mr. Mike Filbin
Mr. and Mrs. Jacob Flanders
Mr. Philip Fleischman
Mr. and Mrs. Dana Garmany
Mr. and Mrs. Bonsal Glascock
Mr. and Mrs. John Graham
Mr. and Mrs. Michael Greenman
Mr. Todd Halberg
Mr. and Mrs. Andrew Hammar
Ms. Cheryl Hintzen-Gaines and
Mr. Ira Gaines
Dr. and Mrs. Jeffrey Hoag
Mr. and Mrs. William Hubble
Mr. and Mrs. J.C. Huizenga
James C. Holleran Jr. Memorial Fund
Dr. Toufic Kachaamy
Kate and Ted Emmerich
Family Foundation
Mr. and Mrs. Jeff Katz
Mr. and Mrs. Matthew Kibbe
Mr. Ilya Koffman
Mr. Nicholas Koopaethes
Mr. and Mrs. Gary Kulbieda
Mr. and Mrs. Jesse Lopez
Drs. Cynthia and Stephen Lynch
Ms. Missie Madeja
Dr. Patrick McCarthy and
Mrs. Lisa Keane McCarthy
Dr. and Mrs. Robert McCulloch
Ms. Karen McPartland
Dr. Jeffrey Metts
Ms. Metta M. Miller
Ms. Alycia Mondavi
Mr. and Mrs. Brent Moser

Ms. Renae Murphy
Ms. Janet Pape
Ms. Jenny R. Patterson and
Mr. Steven L. Kroll
Mr. Rich Pemenko
Ms. Deniz Razon and Mr. Kerr Manson
Mr. and Mrs. Max Sanel
Bill Sasso, Stradley Ronon
Mr. and Mrs. David Scheible
Ms. Pamela Schneck
Mr. and Mrs. Jeff Schwartz
ONEHOPE Foundation
Mr. and Mrs. Donald Smith
Mr. Brandon Soerens
Morgan and Shawn Stephenson
Mr. and Mrs. Robert Stockley
Mr. and Mrs. Mark Tarbell
Team National Hope Foundation
Thrivent Financial for Lutherans
Foundation
Dr. and Mrs. E. Steven Townsend
Dr. and Mrs. Kevin Tulipana
Mr. Jonathan Watkins
Mr. Aaron Wentworth
Mr. and Mrs. Cornel Williams
Dr. and Mrs. Larry Wofford
Dr. and Mrs. Peter C. Yesawich
Dr. and Mrs. Kenny Yoo

CIRCLE OF FRIENDS

\$100 - \$999

Mr. Carlos Abreu
Ms. Hanah Ali
Mr. Douglas Anderson
Mrs. Jo Ann Andrews
Mr. Eric Armstrong
Ms. Susan Avila
Ms. Emma Azadan
Ms. Adrienne Babb
Mr. and Mrs. Steve Baer
Mrs. Rachel Bailey
Ms. Anna Baird
Ms. Karen Baker
Ms. Rosanne Balasabas
Mrs. Brenda Bantle
Mr. DuWayne Barkema
Ms. Elle Bausch
Mr. Nathaniel Beale
Mr. and Mrs. Henry Berns
Mr. Bryan Berry

Dr. Paul Bessonette
Ms. Leslie Beyer
Mr. Roy Black
Ms. Mary Blackwell
Mr. Brent Blandino
Mr. Dan Blaney
Mr. and Mrs. Lawrence Bloxsom
Mr. John Bogucki
Ms. Mary Bond
Mr. and Mrs. Bob Bondurant
Mr. Randy Bosman
Mr. Daniel Bowline
Ms. Ruth Boyd
Ms. Dolores Braswell
Mr. and Mrs. Daniel Brazas
Mr. Scott Brewer
Mr. Al Briggs
J W Briscoe
Ms. Claudia Bruder
Mr. Philip Bruno
Ms. Elizabeth Burgess
Ms. Melissa Burroughs
Ms. Alaina Butler
Mr. and Mrs. Guy Caccavale
Ms. Geri Callender
Dr. Tami Carrillo and Mr. Neil Morrow
Ms. Theresa Carrol
Ms. Cathy Casado
Mr. James Case
Mr. and Mrs. Michael Cencula
Ms. Elizabeth Cesario
Ms. Jessica Cestone
Dr. and Mrs. Sung K. Chang
Mr. Jay Chapman
Ms. Laurel Charles
Mr. Robert Chase
Mr. Filemon Chavarria
Ms. Vivian Su Wei Cheng
Mr. Ned Childs
Ms. Pasquale Chirillo
Mr. and Mrs. Phil Chrysler
Ms. Esther Chu
Ms. Corinne Chung
Ms. Lai Lin Chung
Mr. Joseph Ciccone
City of Ward, Parks and Recreation
Mr. Alan Clouse
Ms. Marissa Coker
Mr. Donato Coletta
Mrs. Karen Collins

Ms. DeAnn Conner
Mr. and Mrs. Richard Cooks
Ms. Shirl Coons
Mr. Michael Coulter Smith
Ms. Judy Craighead
Dr. Miriam Cremer
Ms. Kimberly Czyzowicz
Ms. Susan Dahn
Dr. and Mrs. Robert Darling
Ms. Cathy Davalos
Mr. George Davis
Ms. Marie DeGraeve
Ms. Susan Demers
Mrs. Marti Demetriou
Ms. Martha Den Uyl
Ms. Virginia Diewald
Ms. Beatrice A Dollar
Mr. Rocco Domino
Ms. Angel Downey Price
Mr. Paul Downing
Ms. Mary Dray
Mr. Richard Dutile
Ms. Charlotte Egerton
Mrs. Rita Eisenmann
Ms. Nicole Elizondo
Mr. and Mrs. Tom Evans
Ms. Kristen Felker
Ms. Anne Ferraiuolo
Mr. Aaron Ferris
Mr. Dan Fisk
Ms. Sandy Fitzer
Ms. Nelia S. Fobbs
Ms. Nancy Fortunato
The Foundation of the
Greater Miami Jewish Federation
Ms. Amecha Franks
Ms. Julia Franzese
Dr. Rachel Freedman
Ms. Alexis Freeman
Ms. Letitia Frye
Mr. and Mrs. Arthur Gambell
Mr. Antonio Garcia
Mrs. Stacy Garn
Mr. Michael Geanto
Miss Tina Gee
Mrs. Tonya George
Ms. Yvonne George
Ms. Michele Gergans
Mrs. Marilyn Giglio-Knapp
Mr. and Mrs. Peter R. Glasier

Ms. Vera Glywa
Mr. Michael Glywa
Ms. Marva Goff
Mr. Tom Gohde
Mr. and Mrs. Jake Goldstein
Mr. Shane Gonzales
Mrs. Beatrice Gooding
Mr. Steven Goodwin
Mr. Ophir Gottlieb
Mr. Jeremy Grams
Mr. and Mrs. Scott Graves
Ms. Marla Greco
Ms. Ashley Greer
Mr. Mark Gregory
Mrs. Anges Groff
Mr. Michael Gross
Mr. and Ms. Greg Gruse
Ms. Lori Gunn
Mr. Thomas Gunther
Ms. Joy Guthrie
Mr. Paul Haaland
Ms. Kathleen Hall
Ms. Donna Hall
Mr. Arpi Hamilton
Mrs. Jane Hannon
Mr. William Harris
Mr. Stephen Hart
Mr. and Mrs. Barry A. Hartstein
Mr. David Helms
Mr. Keith Henderson
Ms. Diemlong Hoao
Ms. Terri Hocott
Mr. and Mrs. Ross Hoebing
Mr. and Mrs. William Holland
Holly Shores Campground
Ms. Jen Holsman
Ms. Amy Holtman
Ms. Irina Hot
Ms. Danell Howard
Mrs. Denise Hudy
Mr. and Mrs. Larry Hughes
M O Huntsman
Ms. Cheryl Ingram
Ms. Janielle Jackson-Alvarez
Ms. Marina Jay
Ms. Cynthia Johnson
Ms. Kerri Johnson
Ms. Janet Johnson
Ms. Anne Jones
Mr. Cavelle Jones

Ms. Cynthia Juneau
Ms. Diane Kampmann
Ms. Kristina Kasemir
Mr. Adam Kasick
Mr. and Mrs. Scott Katzman
Mr. Craig Kee
Mr. Patrick Keeble
Ms. Lisa Keenan
Ms. Janice Kelly
Mr. Mark Kelly
Mr. Joseph Kenney
Mr. Muhammad Khan
Mr. and Mrs. Stephen Kiefer
Ms. Cassandra Kilgore
Mrs. Joany Kircher and TJ Gilboy
Mr. Allen Kishma
Ms. Elvira Kisish
Mrs. Eileen Kleinfeldt
Ms. Patricia Klimaszewski
Ms. Heather Knight
Ms. Jamie Kummerlen
Miss Bridgie LaCour
Lambda Alpha
Mrs. Angela Lambert
Ms. Aniya Lamyotte
Ms. Marianne Lanno
Mr. Patrick LaPella
Mr. and Mrs. Andrew Lardner
Mr. David Lauschke
Mr. William Lawler
Mr. Jay Lazar
Ms. Lori Lemke
Mr. Jeffrey Lenz
Mr. Timothy Leonard
Mr. and Mrs. Clifford Levy
Liebovich Steel & Aluminum Co
Mr. Hui Ben Lim
Mr. and Mrs. Ray Lindsay
Mr. Glenn Llopis
Mrs. Monica Lockett
Ms. Brenda Ludington
Ms. Alaina Luisi
Ms. Rosalyn Lunde
Ms. Denise Lundy
Ms. Magnoria Lunsford
Mr. Sean Lyman
Mr. Robert Lyman
Mr. Brian Lynch
Mr. Timothy Mango
Mr. Brian Marks

Ms. Cathy T. Marquez
Mr. Bruce Marshall
Ms. Kathleen Martin
Mr. David Martin
Ms. Kim Francesca Martinez
Mr. Jose Luis Martinez
Mr. Chris Martini
Ms. Carrie Martz
Mr. and Mrs. Gurmeet Masuta
Mr. Shanu Mathew
Mr. Fred Mathies
Ms. Patricia May
Ms. Lori McAninch
Ms. Kathleen P. McAuliffe
Mr. Dennis McBride
Ms. Shelba McBride
Ms. Alice McCleary
Mr. Steve McElhanon
Ms. Dawn McKown
Ms. Stacie McManus
Mr. James McQuiggan
Mrs. Darlene Meese
Ms. Anne Meisner
Mr. Walter Menzel
Mr. and Mrs. Mike Mercier
Ms. Lynn Meyee
Mr. Matthew Michel
Ms. Victoria Milam
Ms. Letty Miles
Mr. Gary Miller
Ms. Mindi Miller
Mr. Donald Mills
Mrs. Alysia Minott
Ms. Robin Mofid
Ms. Zarrin Mohammadi
Ms. Colleen Monahan
Mr. Ivan Montes
Ms. Tamera Moore
Mr. Rod Morganstein
Mrs. Elena Celeste Mosier
Ms. Barbara Muller
Mr. Robert Murray
Mr. Lawrence Murray
Ms. Susan Murray
MVD Connect
Mr. Anthony Myles
Mr. Todd Nerlinger
Mr. Martin Olliff
Ms. Annette Olson
Mr. Thomas Parilo

“I have been a volunteer and donate annually in the name of my friend, Kristi, who lost her battle to cancer at the age of 28. Gateway for Cancer Research is important to me because it focuses on funding Phase I and II clinical trials. This is where the greatest impact is in fighting cancer.”

- Molly Stockley,
Gateway Volunteer Leader

These donations represent cash gifts from July 1, 2020 through June 30, 2021. Gateway has made every attempt to include and highlight the generosity of our donors. If your name is not included on this list and you made a donation of \$100 and above, please let us know.

Mr. Charles Parker
Ms. Judith Parnock
Patrick Automotive Group
Ms. Chris Pawlowski
Ms. Lynwood Payne
Mr. and Mrs. Dennis Pearson
Mr. and Mrs. Larry Penix
Mr. Sam Perera
Mr. and Mrs. Scott Pfeifer
Mr. Linton Phillips
Mr. and Mrs. Phillip Picchietti
Ms. Angela Pierce
Pioneer Telephone Cooperative
Ms. Tracy Pitts
Mr. John Prospero
Ms. Cheryl Ramirez
Mr. Rene Ramirez
Mr. Eric Ramos
Rearick Tooling Inc. / JIT
Mr. Corey Reeder
Ms. Jennifer Reeves
Ms. Erin Renzi
Mr. Dave Riggs
Ms. Elizabeth Riley
Mr. Gregg Riley
Mr. Keith Ripper
Mr. and Mrs. Joe Rogers
Mr. and Mrs. Louis Roitblat
Mrs. Maria Ryan
Ms. Janette Saenz
Mr. John Santoro
Mr. Joseph Scavone
Mr. Eugene Schempp
Mr. and Mrs. Bryan Schmidt
Ms. Lynn Schoenberg
Mrs. Kim Schwartz
Mr. Scott Sepulvado
Mr. David Sewall
Ms. Pam Sherbia
Kappa Alpha Sigma,
Sigma Gamma Rho Sorority, Inc.
Mr. Michael Simmons
Ms. Jeanette Singleton
Ms. Christy Sisson
Mrs. Linda Smith
Ms. Keri Smith
Ms. Samantha Smith
Mr. James Snyder
Mr. Thomas Stavredes
Ms. Sue Stevens
Ms. Natalie Stewart
Ms. Kimberly Stone
Mr. Robert Stott
Ms. Janet Summers
Ms. Rose Swafford
Mr. Charles Sweeney
Mr. Robert Swettman
Mr. and Mrs. James Talbert
TapQA
Target Corporation
Ms. Eileen Taylor
Mrs. Charlene Taylor
John and Kristina Telano
Ms. Emily Thomas
Ms. Patty Thomas
Colonel James D. Thompson
Mr. and Mrs. Stephen Thompson
Ms. Suzanne Treter
Ms. Diana Trzaska
Ms. Danielle Turner
Mr. and Mrs. Will Turner
Ms. Sherron Turner
Ms. Angie Udelhofen
Ms. Staci Vernick
Ms. Jennifer Vicidomine
Ms. and Phyllis Vieira
Ms. Sandy Vossler
Ms. Joan Walldan
Mr. Caprice Walters
Mr. and Mrs. Corey Walz
Mrs. Alexandria Waters
Mr. Mark Watson
Mr. Gary Weese
Ms. Elizabeth Welsh
Ms. McKenna Wesley
Ms. Maryrose N. White
Ms. Natalya Williams
Ms. Kara Williams
Mr. Grant Williams
Mr. Jeffrey Williams
Mr. Samuel Wilson
Mr. Bruce Wiltbank
Mr. Kalman Winnick
Mr. and Mrs. David Winter
Ms. Lauren Wolf
Mr. Jeff Wright
Mr. Randall Wright
Mr. Robert Wynn
Ms. Janet Yocum
Ms. Janine Zaremba

LEADERSHIP

BOARD OF DIRECTORS

Richard J Stephenson
CHAIRMAN

Dr. Stacie J. Stephenson
VICE CHAIR

Fred DeGrandis
SECRETARY

Timothy Flanigan
ASSISTANT SECRETARY

Tony Festa
TREASURER

Amy Belew

Tawnya Bond

Michael Burton
(ex officio)

Joe Caltabiano

Jake Goldstein

Dr. Emanuel Petricoin

Deniz Razon

Edwin Roberson

Mary Lou Smith

Dr. Satish Tadikonda

RESEARCH AND GRANTS COMMITTEE

**BOARD OF DIRECTORS
LIAISON**

Dr. Emanuel Petricoin

Mary Lou Smith

Deniz Razon

MD/PHD

Dr. Sameek Roychowdhury –
Peer Review, Chair

Dr. Edward Kim

Dr. Alberto Pappo

Dr. Tim Fleming

Dr. Ronald Morton

Dr. Jordi A. Rodon

Dr. Vivek Subbiah

PATIENT ADVOCATE

Rich Rieger



ASSOCIATES BOARD

Danny Cameron
BOARD CO-CHAIR

Catherine Lyman
BOARD CO-CHAIR

Corey Walz
TREASURER

David Lauschke
SECRETARY

Elle Bausch
COMMUNICATIONS CHAIR

Christi Turner
**MEMBERSHIP &
ENGAGEMENT CHAIR**

Neira Hot
MISSION CONNECTION CHAIR

Robert Watson
SPONSORSHIP CHAIR

MEMBERS

Dan Frett

TJ Gilboj

Emmanuel Lopez

Julia Pfieler

Shelby Stephenson

Jillian Stevens

Max Strommen

Josh Udelhofen

FINANCIAL HIGHLIGHTS

FUNDRAISING REVENUE

Contributions	\$2,855,488
Special Events	\$528,550
Total Fundraising Revenue	\$3,384,038

RESEARCH GRANTS

Awarded Grant Funds	\$7,740,828
---------------------	-------------

ASSETS

Cash and Cash Equivalent	\$3,355,689
Pledges and Other Receivables	\$1,957,197
Investments	\$13,594,909
Prepaid Expenses	\$0
Interests in Limited Partnerships	\$8,350
Total Assets	\$18,916,145

LIABILITIES

Accrued Grants	\$11,712,918
Accounts Payable	\$51,310
Deferred Revenue	\$800,000
Deferred Revenue	\$20,260
Total Liabilities	\$12,584,488

NET ASSETS

\$6,331,657

TOTAL LIABILITIES AND NET ASSETS

\$18,916,145



CONNECT WITH GATEWAY



GATEWAY
FOR CANCER RESEARCH

   
@gatewayforcr

500 EAST REMINGTON ROAD, SUITE 200, SCHAUMBURG, IL 60173 | GATEWAYCR.ORG | 888-221-2873